On December 6, 2019 TG Therapeutics, Inc. (NASDAQ: TGTX), reported the schedule of triple therapy data presentations, at the upcoming 61stAmerican Society of Hematology (ASH) (Free ASH Whitepaper) annual meeting and exposition, to be held December 7 – 10, 2019, at the Orange County Convention Center in Orlando, FL (Press release, TG Therapeutics, DEC 6, 2019, View Source [SID1234552004]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentations at the ASH (Free ASH Whitepaper) 2019 meeting include the following:
Oral Presentation Details:
Title: A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Publication Number: 360
Oral Session: 642. CLL: Therapy, excluding Transplantation: Combination and Novel Treatment
Session Date and Time: Sunday, December 8, 2019; 7:30 AM – 9:00 AM ET
Presentation Time: 8:45 AM ET
Location: Orange County Convention Center, Hall E1
Presenter: Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
Poster Presentation Details:
Title: Phase 1 Study of TG-1701, a Selective Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Patients with Relapsed/Refractory B-Cell Malignancies
Publication Number: 4001
Session: 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma—Clinical Studies: Poster III
Date and Time: Monday, December 9, 2019; 6:00 PM – 8:00 PM ET
Location: Orange County Convention Center, Hall B
Presenter: Chan Cheah, MD, Sir Charles Gairdner Hospital, Hollywood Private Hospital, University of Western Australia, Blood Cancer Research Western Australia